Top 50 Biotechnology VC Funds & Investors in Austria (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
XISTA Science Ventures
VC Fund
|
12 | Austria, France, Slovenia | Seed, Pre-Seed, Series A | Biotechnology, Medical, Software | $511k–$20M |
|
xista science ventures
VC Fund
|
9 | Austria, Slovenia | Seed, Pre-Seed, Series A | Biotechnology, Medical, Software | $511k–$20M |
|
tecnet equity
VC Fund
|
7 | Austria | Seed, Series A | Software, SaaS, Biotechnology | $400k–$6M |
|
SOSV
VC Fund
|
5 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
austria Wirtschaftsservice (aws)
VC Fund
|
5 | Austria, Belgium | Seed, Grant, Pre-Seed | Software, Information Technology, SaaS | $44k–$2.2M |
|
MIG Capital
VC Fund
|
4 | Germany, France, Austria | Series A, Series B | Biotechnology, Health Care, Therapeutics | $1.6M–$54M |
|
aws Gründungsfonds
VC Fund
|
3 | Austria, Germany, United States | Seed, Series A | Software, SaaS, Information Technology | $1.1M–$12M |
|
VP Venture Partners
VC Fund
|
2 | Austria, Switzerland | Seed | Medical, Health Diagnostics, Internet | $3M–$3.3M |
|
Lansdowne Partners
VC Fund
|
2 | United Kingdom, Austria, United States | Series A, Series B | Biotechnology, Finance, Genetics | $6.8M–$100M |
|
10x Founders
VC Fund
|
2 | Germany, United States, Switzerland | Seed, Series A, Pre-Seed | Software, Information Technology, Artificial Intelligence | $1.1M–$60M |
|
Aescap Venture
VC Fund
|
2 | United Kingdom, Austria, Belgium | Series A, Series B | Biotechnology, Pharmaceutical, Chemical | $1.5M–$33M |
|
PUSH VC
VC Fund
|
2 | Austria, Germany, United States | Seed, Series A | Software, Apps, Health Care | $650k–$32M |
|
APEX Ventures
VC Fund
|
2 | Germany, United Kingdom, Austria | Seed, Series A, Pre-Seed | Artificial Intelligence, Software, Health Care | $511k–$21M |
|
Gamma Capital Partners
VC Fund
|
2 | Austria, United States, Germany | Series A, Seed | Software, Manufacturing, Information Technology | $406k–$8M |
|
Arax Capital Partners
VC Fund
|
2 | Austria | Seed | Biotechnology, Health Care, Medical | |
|
bmp Ventures
VC Fund
|
2 | Germany, United States, Austria | Seed, Series A | Software, Information Technology, Manufacturing | $30k–$5.9M |
|
FPS-Holding
VC Fund
|
2 | Austria | Seed | Biotechnology, Health Diagnostics | $420k–$429k |
|
BackBone Ventures
VC Fund
|
2 | Switzerland, Germany, Israel | Pre-Seed, Seed, Series A | Artificial Intelligence, Information Technology, Software | $583k–$105M |
|
red-stars.com
VC Fund
|
2 | Austria, Germany | Seed, Series A | Software, Biotechnology, Telecommunications | $1.6M–$4.4M |
|
The Austrian Research Promotion Agency (FFG)
VC Fund
|
2 | Austria, United States, Belgium | Grant, Seed, Pre-Seed | Software, Artificial Intelligence, Medical | $67k–$3.5M |
|
TSVC
VC Fund
|
2 | United States, China, Canada | Seed, Series A | Software, Artificial Intelligence, Health Care | $500k–$27M |
|
Nina Capital
VC Fund
|
2 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $573k–$22M |
|
R42 Group
VC Fund
|
2 | United Kingdom, United States, Austria | Seed, Pre-Seed | Biotechnology, Health Care, Software | $439k–$4M |
|
Longevitytech.fund
VC Fund
|
2 | United States, United Kingdom, The Netherlands | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Life Science | $439k–$10M |
|
Übermorgen Ventures
VC Fund
|
2 | Germany, Switzerland, Finland | Seed, Pre-Seed, Series A | Software, Energy, Renewable Energy | $344k–$12M |
|
eQventure
VC Fund
|
2 | Austria, Switzerland | Seed, Series A | Software, Information Technology, Artificial Intelligence | $549k–$6.6M |
|
Synthesis Capital
VC Fund
|
1 | United States, Israel, Austria | Seed, Series A | Biotechnology, Food and Beverage, Organic Food | $7.1M–$23M |
|
42CAP
VC Fund
|
1 | Germany, France, Sweden | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, SaaS | $1.3M–$19M |
|
GLS Ventures
VC Fund
|
1 | Austria | Series B | Medical, Health Care, Biotechnology | |
|
EIT Health
VC Fund
|
1 | United Kingdom, Spain, Ireland | Grant, Pre-Seed, Seed | Health Care, Medical Device, Medical | $22k–$1.6M |
|
HackCapital
VC Fund
|
1 | United States, Israel, United Kingdom | Seed, Pre-Seed, Series A | Biotechnology, Food and Beverage, Food Processing | |
|
Auxxo
VC Fund
|
1 | Germany, United Kingdom, France | Seed, Pre-Seed, Series A | Software, Health Care, FinTech | |
|
Sofinnova Partners
VC Fund
|
1 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$102M |
|
Venture Partners AG
VC Fund
|
1 | Austria, United States | Seed, Series B | Internet, Software, Biotechnology | |
|
Hadean Ventures
VC Fund
|
1 | Norway, Sweden, Germany | Series A, Series B | Biotechnology, Health Care, Medical | $4.3M–$79M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
1 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.3M–$50M |
|
Amino Collective
VC Fund
|
1 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Medical | $125k–$26M |
|
Possible Ventures
VC Fund
|
1 | Germany, Australia, United States | Seed, Pre-Seed, Series A | Software, Biotechnology, Information Technology | $549k–$44M |
|
Credit Agricole CIB
VC Fund
|
1 | France, United States, United Kingdom | Debt Financing, Series A, Post-IPO Debt | Energy, Solar, Renewable Energy | |
|
i&i Biotech Fund
VC Fund
|
1 | Czech Republic, India, Spain | Seed, Series A | Biotechnology, Health Care, Medical | |
|
INVEST AG
VC Fund
|
1 | Austria, United States | Seed, Private Equity | Security, Hospitality, Food and Beverage | |
|
Verge HealthTech Fund
VC Fund
|
1 | Estonia, Singapore, United Kingdom | Seed, Pre-Seed, Series A | Health Care, Medical Device, Medical | |
|
FastVentures
VC Fund
|
1 | Hungary, South Korea, United States | Seed, Series A, Series B | Software, Biotechnology, Information Technology | $424k–$31M |
|
ICL Planet Startup Hub
VC Fund
|
1 | Israel, Austria | Seed | Biotechnology, Agriculture, Organic Food | |
|
Simon Capital
VC Fund
|
1 | Germany, Austria | Seed, Series A, Series B | Software, Biotechnology, SaaS | |
|
EMBL Ventures
VC Fund
|
1 | Germany, Austria, Ireland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.9M–$70M |
|
Techno Venture Management
VC Fund
|
1 | United States, Germany, United Kingdom | Series B, Series A | Biotechnology, Health Care, Pharmaceutical | |
|
Ligand Pharmaceuticals
VC Fund
|
1 | United States, Austria | Corporate Round, Post-IPO Debt, Series A | Health Care, Biotechnology, Medical | |
|
Clima Now
VC Fund
|
1 | Switzerland, Germany, Austria | Seed, Grant, Pre-Seed | Farming, Renewable Energy, Solar | |
|
Wlanholding GmbH
VC Fund
|
1 | Austria | Seed | Medical, Health Care, Biotechnology | |
| Access all 138 VC funds in Austria Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
We invest in deep tech startups and academic spin-offs with a strong innovation based on science, engineering and technology. We invest as lead investor in pre-seed and seed stages and have the ability to follow on in later rounds. We understand the needs of science and tech based startups and offer tailored support for entrepreneurs. We areembedded in the venture capital scene, yet understand the language of science and the world of research. Thanks to our diverse team, our expertise and experience in technology, entrepreneurship, finance, legal, IP, and strategic consulting will support your startup right from the start.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Austria, France, Slovenia
Investor stats
- Total investments: 30
- Round size: Seed $576k–$7.8M; Pre-Seed $511k–$1.4M; Series A $5.2M–$20M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- nista.io — gnista.io is a no code data clearing tool for energy managers.
- contextflow — contextflow revolutionizes the medical information search process with the help of deep learning: our 3D image-based search engine for radiologists looks for regions of interest within images (currently 18+ patterns in lung CTs); when a suspicious pattern is detected, we immediately find visually similar cases, descriptions and relevant referenceinformation, affording doctors easy access to knowledge currently hidden in large medical image data and their associated reports...all within seconds. No more paging through books, guessing the right keyword or consulting various text-based reference search engines. In addition, our software can be configured to allow for prioritization of cases where patterns of interest are detected.contextflow is a spin-off of the Medical University of Vienna (MUW), Technical University of Vienna (TU) and European research project KHRESMOI. Founded by a team of AI and engineering experts in July 2016, the company was awarded the distinction of Most Promising Startup by the BCS Search Industry, received the Digital Innovation Award by the Austrian Federal Ministry of Education, Science and Research and was selected as one of 19 startups out of over 700 applications to participate in the Philips HealthWorks accelerator program. It is currently testing its 3D image-based software with six partners, expanding internationally to other locations later this year.
- G.ST Antivirals — G.ST Antivirals focuses on the development of antiviral drugs. G.ST Antivirals utilizes the viral dependency on the host cell metabolism and exploits this to design specific interventions counteracting viral nutrient supply.
We invest in deep tech startups and academic spin-offs with a strong innovation based on science, engineering and technology. We invest as lead investor in pre-seed and seed stages and have the ability to follow on in later rounds. We understand the needs of science and tech based startups and offer tailored support for entrepreneurs. We areembedded in the venture capital scene, yet understand the language of science and the world of research. Thanks to our diverse team, our expertise and experience in technology, entrepreneurship, finance, legal, IP, and strategic consulting will support your startup right from the start.
Show more...Investment focus
- Industry: Biotechnology, Medical, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Austria, Slovenia
Investor stats
- Total investments: 22
- Round size: Seed $1.8M–$7.8M; Pre-Seed $511k–$1.4M; Series A $5.2M–$20M
- Lead/follow: 64% lead, 36% follow
Portfolio highlights
- subdron — subdron turns the seabed from a blind spot into a monitored domain.
- infrared.city — Redefine environmental simulations. Our bespoke AI models revolutionise performative design, slashing time, cost, and complexity. Access cutting-edge services effortlessly because innovation should be for everyone
- VALANX Biotech — VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
tecnet equity is an Austrian venture capital fund investing in innovative high-tech companies with potential for significant growth.
Show more...Investment focus
- Industry: Software, SaaS, Biotechnology
- Stage:Seed, Series A
- Geography: Austria
Investor stats
- Total investments: 60
- Round size: Seed $400k–$2.5M; Series A $583k–$6M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2009
Portfolio highlights
- Sipfront — Sipfront helps telecom operators to deliver better services by automating 24/7 active monitoring and by providing a test framework to simulate customer calls at scale
- Orderlion — Streamline your wholesale business with Orderlion's ordering app. Automate orders, boost sales, and enhance customer loyalty. Find out more!
- VALANX Biotech — VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
The Austrian Economic Service mbH (aws) is the promotional bank of the Federal Government.The aws SME fund is the largest Austrian Fund for silent corporate investments, but also providers of equity. Founded in late 2009 by the Austrian Economic Service mbH (aws) - the Development Bank of the Federal - he has a term until 31/12/2025.The fund is currently endowed with EUR 80 million and participates in medium-sized companies and brings with it a fresh capital to develop new products or processes, for sales development to international expansion.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Grant, Pre-Seed
- Geography: Austria, Belgium
Investor stats
- Total investments: 56
- Round size: Seed $439k–$2.2M; Grant $64k–$603k; Pre-Seed $44k–$1.9M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- Repentium — Repentium serves industrial manufacturers seeking reproducible, cost-efficient 3D printing and engineering-grade plastic parts.
- Another Earth — Another Earth is building an AI-powered simulation and synthetic data platform for Earth Observation. As our planet changes, AI models need scalable, high-quality training data to keep pace. Another Earth provides synthetic data, scenario simulations and predictions required to accelerate AI development, and enable faster, smarterdecision-making—enabling smarter decisions for a more resilient world.
- Cycuria Therapeutics — While new therapies, such as FLT3 inhibitors and venetoclax-based regimens, have improved initial response rates, durable remissions and long-term survival
MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: Germany, France, Austria
Investor stats
- Total investments: 93
- Round size: Series A $2.2M–$28M; Series B $1.6M–$54M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $70M in 2014
Portfolio highlights
- AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.
- Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
- ASTRA Therapeutics — Astra - Therapeutics
aws Gründerfonds is Austria's 70m venture capital fund. We invest as co-investor in Austrian high-growth start-ups in their later seed and (pre-)series-A stages.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Seed, Series A
- Geography: Austria, Germany, United States
Investor stats
- Total investments: 83
- Round size: Seed $1.1M–$5.2M; Series A $1.1M–$12M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Upnano — Upnano engages in the manufacture and commercialization of 3D printing systems.
- OPTIMUSE — Optimuse provides an AI-based solution that supports the pre-design phase of building renovation. The platform converts building data into a digital twin to create accurate models for planning. It integrates data such as room types, thermal properties, and HVAC systems. The system runs energy simulations to calculate heating, cooling, lighting, andequipment needs. It helps design technical systems by defining the quantity, sizing, and configuration of components. The platform develops renovation plans by modeling financial, energy, and emissions outcomes. It also offers tools for cost calculation, performance monitoring, and collaboration across project teams.
- HelloBello — HelloBello offers freshly cooked and cooled delivered human-grade food tailored to each dog’s nutritional needs. HelloBello is a PetTech company with a strong focus on the German speaking markets (for now). HelloBello’s personalized meals are free of any by-products and are portioned, packaged, and delivered directly to your door. By working with aspecialized veterinarian, HelloBello is able to derive each dog’s exact nutritional needs based on a proprietary algorithm. The recipes are made of natural sources like millet and seaweed, instead of heavy use of supplements, which makes it easier for the dog to absorb and get true nutritional benefits.Our credo in German is " ... Frisch. Individuell. Geliefert. - Frischfutter ist einfach besser ..."
VP Venture Partners is a venture capital firm invests in healthcare companies.
Show more...Investment focus
- Industry: Medical, Health Diagnostics, Internet
- Stage:Seed
- Geography: Austria, Switzerland
Investor stats
- Total investments: 3
- Round size: Seed $3M–$3.3M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Diamens — Diamens is a company focused on femtech that develops a non-invasive menstrual blood-based molecular diagnostic to detect women-specific diseases like endometriosis.
- Moonlight AI — Moonlight AI empowers pathologists and hematologists to make therapeutic decisions backed by genomic insight. Moonlight AI was founded in 2022 and is headquartered in Jura, Switzerland.
- aTension.life — aTension.life is a company focused on advancing the diagnosis and treatment of hypertension through precision medicine. It employs cutting-edge mass spectrometry technology to identify the underlying causes of uncontrolled hypertension using a single blood sample. aTension.life aims to provide personalized diagnostic solutions that enhance patientcare and support laboratories with accurate and reliable tools. The company's mission is to improve the quality of life for hypertensive patients by making advanced diagnostics widely accessible and enabling more effective, individualized therapies.
Fundamental Equity Investing, since 1998
Show more...Investment focus
- Industry: Biotechnology, Finance, Genetics
- Stage:Series A, Series B
- Geography: United Kingdom, Austria, United States
Investor stats
- Total investments: 43
- Round size: Series A $6.8M–$55M; Series B $8.5M–$100M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Nattergal — Nattergal is a company with a mission to deliver nature recovery at scale, to provide vital benefits for society and sustainable financial returns.
- G.ST Antivirals — G.ST Antivirals focuses on the development of antiviral drugs. G.ST Antivirals utilizes the viral dependency on the host cell metabolism and exploits this to design specific interventions counteracting viral nutrient supply.
- amnis — Check out your possibilities to transfer money abroad, collect international payments and exchange currencies all in one account. Make payments fast with amnis.
Cutting-edge venture capital firm supporting the early-stage entrepreneurs building global businesses.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United States, Switzerland
Investor stats
- Total investments: 86
- Round size: Seed $2.7M–$12M; Pre-Seed $1.1M–$12M; Series A $6.9M–$60M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Raus — Raus is a hospitality-tech startup that offers new opportunities to take a break from big city life. Raus serves as a welcome escape from the seemingly endless demands and constant stimuli of modern life with perfectly simple cabins, close enough for a spontaneous getaway, far enough away to completely unwind.
- Cylib — The cylib process transfers waste from end of life batteries or production scrap into marketable products. Cylib covers all steps from the discharging of batteries up to hydrometallurgical extraction. Since the whole process is in one hand, also the processing of production scraps as well as black mass is possible.
- Penny — Find all your old pensions, automatically. UK Fintech Awards Pension-tech of the year.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Aescap Venture is an Amsterdam-based investment company that pursues investments in biotech companies in Europe and the U.S.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Chemical
- Stage:Series A, Series B
- Geography: United Kingdom, Austria, Belgium
Investor stats
- Total investments: 18
- Round size: Series A $1.5M–$20M; Series B $5.2M–$33M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Biocartis — Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus on oncology.
- Vivendy Therapeutics — Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly
- Affectis Pharmaceuticals — Affectis is a pharmaceuticals company developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases.
| Investments that move industries
Show more...Investment focus
- Industry: Software, Apps, Health Care
- Stage:Seed, Series A
- Geography: Austria, Germany, United States
Investor stats
- Total investments: 35
- Round size: Seed $650k–$8.1M; Series A $5M–$32M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Emmi AI — Emmi AI thinks that the nexus of physics and artificial intelligence represents the next frontier in industrial engineering. The world of large-scale engineering and manufacturing is ripe for transformation, yet today's innovation processes are hindered by slow, costly simulations and prohibitive computational requirements.
- Voltrac — Voltrac is a robotics company that develops an autonomous, fully electric tractor platform called THOR, designed to operate in demanding environments for both agricultural and logistics use. THOR employs per-wheel electric motors instead of a conventional drivetrain, reducing mechanical complexity and maintenance requirements. It runs on swappable200 kWh battery packs, enabling long-duration operations and continuous work cycles. The platform supports a standard three-point hitch (Category II) and can be configured with a flatbed, making it versatile for fieldwork or transport tasks. Voltrac’s autonomy system combines reinforcement learning with real-time sensor data to adapt driving behavior and implements to changing terrain and crop conditions. Beyond farming, THOR is also intended for frontline logistics missions, with modular designs that can support cargo transport and resilience in challenging settings.
- Circonomit — Building the world's environmental data infrastructure - We are the sustainability counterpart to what Excel, Sheets and Datev are to financial planning and accounting. Our mission is to create the first decision intelligence platform to bridge sustainability and finance by building the global standard for the collection and aggregation ofcorporate environmental data.
APEX Ventures is a deep-tech and medical-focused venture capital firm.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United Kingdom, Austria
Investor stats
- Total investments: 53
- Round size: Seed $1.3M–$8M; Pre-Seed $511k–$3M; Series A $2.2M–$21M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- GEMESYS — Gemesys creates a chip that functions similarly to the human brain in order to overcome processing constraints and empower AI with the hardware it needs to complete its destiny
- HyperHeat — HyperHeat is building a cutting-edge, all-electric heating solution designed to reach temperatures of up to 2,000°C. Using renewable electricity HyperHeat is providing an efficient alternative to fossil fuel combustion. With an efficiency rate of up to 98%, HyperHeat is ideal for retrofitting industrial processes, enabling significant CO2reductions across industries like steel, cement, and chemicals. The scalable technology offers a cost-efficient approach to decarbonizing thermal processes, with a potential to reduce global CO2 emissions by over 4.5 gigatons annually.
- TriLite Technologies — The world's smallest projection displays from TriLite take laser beam scanning technology to the next level, for augmented vision as light as the eyewear of today.
gcp gamma capital partners is an independent Venture Capital investment firm, focused on financing dynamic technology companies in Austria, Germany, Switzerland and CEE countries.They seek to achieve superior returns by finding assets with substantial potential in their regional and sectoral focus areas, before they appear on the radar screenof mainstream players in terms of stage and/or initial investment size.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Series A, Seed
- Geography: Austria, United States, Germany
Investor stats
- Total investments: 29
- Round size: Seed $406k–$636k; Series A $1.3M–$8M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Icomasoft — Icomasoft ag is a Swiss pioneer of agent-less software solutions providing unprecedented transparency across your virtual and physical IT infrastructure in heterogeneous datacenters.IcomasoftÂ:registered: software solutions collect essential information for mission-critical and business-critical decisions and provide simplified, automated tasksthat support administrators, IT managers and Executives to easily and confidently analyze, plan and optimize their IT capacity. icomasoftÂ:registered: software solutions are vital for your datacenter clarity.
- Henn GmbH & Co KG — Henn GmbH & Co KG develops and commercializes rapid connecting systems for hoses in automotive engine blocks.
- CNSystems Medizintechnik — CNSystems Medizintechnik sells, manufactures, and develops equipment for non-invasive, continuous monitoring of blood pressure and other essential vital parameters. The company was founded in May 1998 as a spin-off from the Medical University and University of Technology Graz, Austria.
ARAX Capital Partners is an Austrian bio-tech and high-tech early stage investor with an exclusive focus on Austrian ventures. Companies need to be young, innovative (if possible with patentable technology) and must have already secured pre-seed funding to qualify for an investment
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed
- Geography: Austria
Investor stats
- Total investments: 5
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- AFFiRiS — AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions.
- Greenpass — Greenpass is a ClimateTech company providing the official greenpass for climate proof real estate. Build resilience and manage climate-proof assets and portfolios in line with ESG regulations while maximizing return on invest and value with ease.
- Calyxha Biotechnologies GmbH — A new perspective on inflammation
bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Seed, Series A
- Geography: Germany, United States, Austria
Investor stats
- Total investments: 118
- Round size: Seed $151k–$3.4M; Series A $30k–$5.9M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Sedivention — Fight obesity within 20 minutes - fast, effective, long-term. A new weight-loss therapy for the treatment of obesity. Just a view minutes will change your life.
- Solar Materials — SOLAR MATERIALS developed a recycling technology for solar modules, which recovers all raw materials for a circular solar industry.
- Litherm Technologies — Litherm Technologies GmbH is a German deep‑tech startup focused on decarbonizing lime and cement production using fully electric kiln technology.
SPV
Show more...Investment focus
- Industry: Biotechnology, Health Diagnostics
- Stage:Seed
- Geography: Austria
Investor stats
- Total investments: 2
- Round size: Seed $420k–$429k
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Sola Diagnostics — Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics.
BackBone Ventures' focus are early-stage investments, primarly in the area of innovative ICT, FoodTech and disruptive technologies in DACH & Israel. Committed to achieve a positive impact for the next generation by empowering access to proficient ventures investments.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, Germany, Israel
Investor stats
- Total investments: 69
- Round size: Seed $966k–$5M; Pre-Seed $583k–$2.1M; Series A $5M–$105M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Neon — With neon, you can pay, save and manage your money. Digitally, securely and with no hidden fees. Open your account online in less than 10 minutes!
- Evoralis — Evoralis is an enzyme development company that specializes in the discovery and development of plastic-depolymerizing enzymes. It is a spin-out from the University of Cambridge.
- Proofcheck — Proofcheck is a multilingual AI proofreading platform and a collaborative in-browser workspace for PDFs and epubs. Their next-generation AI workflow and collaboration tool helps content creators quickly catch costly mistakes before they reach audiences. Proofcheck is headquartered in Vienna, Wien and was founded in 2022.
We back B2B software and life-sciences companies with limitless scalability.
Show more...Investment focus
- Industry: Software, Biotechnology, Telecommunications
- Stage:Seed, Series A
- Geography: Austria, Germany
Investor stats
- Total investments: 8
- Round size: Seed $1.6M–$4.4M
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- Txture — End-To-End Cloud Transformation Platform
- HeartBeat.bio — HeartBeat.bio is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies.
- MAVOCO — We create a carrier-grade software for IoT champions, trusted by tier-1 Mobile network operators.
The Austrian Research Promotion Agency (FFG) is the national funding agency for industrial research and development in Austria. As a "one-stop shop" offering a diversified and targeted programme portfolio, the FFG gives Austrian businesses and research facilities quick and uncomplicated access to research funding.The FFG was foundedon 1 September 2004 (pursuant to the FFG Act on establishing a research promotion agency, Federal Law Gazette I No. 73/2004). The FFG is wholly owned by the Republic of Austria, represented by the Federal Ministry for Transport, Innovation and Technology (bmvit) and the Federal Ministry of Science, Research and Economy (BMWFW). As a provider of funding services, however, the FFG also works for other national and international institutions.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Medical
- Stage:Grant, Seed, Pre-Seed
- Geography: Austria, United States, Belgium
Investor stats
- Total investments: 69
- Round size: Seed $300k–$2.2M; Grant $67k–$3.5M; Pre-Seed $480k–$1.9M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Chatlyn — Automated, AI-enhancend guest engagement, where your clients are most comfortable.
- OPTIMUSE — Optimuse provides an AI-based solution that supports the pre-design phase of building renovation. The platform converts building data into a digital twin to create accurate models for planning. It integrates data such as room types, thermal properties, and HVAC systems. The system runs energy simulations to calculate heating, cooling, lighting, andequipment needs. It helps design technical systems by defining the quantity, sizing, and configuration of components. The platform develops renovation plans by modeling financial, energy, and emissions outcomes. It also offers tools for cost calculation, performance monitoring, and collaboration across project teams.
- Another Earth — Another Earth is building an AI-powered simulation and synthetic data platform for Earth Observation. As our planet changes, AI models need scalable, high-quality training data to keep pace. Another Earth provides synthetic data, scenario simulations and predictions required to accelerate AI development, and enable faster, smarterdecision-making—enabling smarter decisions for a more resilient world.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Founded in 2010, TSVC (formerly TEEC Angel Fund) is proud to be a leading early-stage venture capital fund in Silicon Valley.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A
- Geography: United States, China, Canada
Investor stats
- Total investments: 234
- Round size: Seed $500k–$7M; Series A $2M–$27M
- Lead/follow: 8% lead, 92% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Dexmate — Dexmate is a robotics startup focused on developing general-purpose mobile robots. The company specializes in robots with manipulation capabilities. Their technology aims to enhance automation across various industries.
- EGI Battery — EGI Battery manufactures batteries for autonomous systems, aviation, robotics, and mobility.
- Petal Surgical — Petal is a surgical technology company pioneering incisionless surgery through Acoustic Sculpting, a proprietary form of boiling histotripsy. Our platform uses focused sound waves to precisely destroy harmful tissue without cuts, heat, or toxicity offering gentler alternative to traditional surgery.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 81
- Round size: Seed $2M–$5.2M; Pre-Seed $573k–$2.4M; Series A $5M–$22M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- io Health — Io Health Technologies LLC provides AI-driven tools for home health documentation and workflow automation in healthcare.
- Sober Sidekick — Gamified peer to peer support
R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, Austria
Investor stats
- Total investments: 27
- Round size: Seed $654k–$4M; Pre-Seed $439k–$2M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
- xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
- Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.
Investing globally in technologies extending healthy lifespans
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 48
- Round size: Seed $1.7M–$10M; Pre-Seed $439k–$3.2M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Klothea Bio — Klothea Bio is a protein well known for its powerful anti-aging capabilities, such as tumor suppression, neuroprotection, and antioxidative actions. As people age, their klotho levels drop to harmful levels. The metabolic disease syndrome will be the focus of the first investigations, while later studies will try to extend therapeutic applicationsto cancer, Alzheimer's disease, obesity, and other age-related diseases.
- Yuva Biosciences — Using cutting edge mitochondrial science to develop cosmeceuticals and pharmaceuticals.
- MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
We are an early stage VC for climate tech startups.
Show more...Investment focus
- Industry: Software, Energy, Renewable Energy
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Switzerland, Finland
Investor stats
- Total investments: 48
- Round size: Seed $2.2M–$6.2M; Pre-Seed $344k–$4.2M; Series A $2.7M–$12M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Ecair — Ecair provides software for indoor air quality and energy management. The platform aggregates data from connected sensors to track pollutants, CO2, humidity, temperature, and particulate matter in real time. Dashboards, alerts, and APIs support building operations, facility managers, and ESG teams. Algorithms estimate exposure, flag ventilationissues, and suggest HVAC adjustments to balance comfort, health, and energy use. Reporting tools support certifications and compliance, and data exports integrate with BMS, CMMS, and data warehouses. Services include device provisioning, calibration management, and analytics consulting for multi-site portfolios.
- Carbo Culture — We are a project developer with proprietary climate technology. We are building a rapidly scalable biochar carbon removal solution.
- Milvus Advanced — Our Midas-touch alloys replicate the functional properties of platinum-group metals at a fraction of the cost.
Entrepreneurs for Entrepreneurs
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A
- Geography: Austria, Switzerland
Investor stats
- Total investments: 57
- Round size: Seed $549k–$1.2M; Series A $768k–$6.6M
- Lead/follow: 79% lead, 21% follow
Portfolio highlights
- Diamens — Diamens is a company focused on femtech that develops a non-invasive menstrual blood-based molecular diagnostic to detect women-specific diseases like endometriosis.
- Respory — Respory provides real-time people-tracking using proprietary radar sensors, all without capturing personal data. Our scalable sensor network, powered by AI-driven algorithms, delivers precise customer journey insights, critical for in-store performance in retail.
- 2nd Cycle — 2nd Cycle creating a cost-effective, fully automated, and scalable solution for modules for a second life cycle.
Synthesis Capital is an investment manager transforming our food system through food technology.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Organic Food
- Stage:Seed, Series A
- Geography: United States, Israel, Austria
Investor stats
- Total investments: 9
- Round size: Seed $7.1M–$9M; Series A $20M–$23M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Triplebar — Triplebar provides sustainability, biotechnology, and synthetic biology research.
- Savor — Savor makes delightfully rich foods without animals, farmland, fertilizers, hormones, or antibiotics.
- Hyfé — Hyfé Foods is a biotech company producing ingredients by leveraging fungal fermentation to upcycle water byproducts from food manufacturers.
We are peers amongst entrepreneurs helping the brave to build game-changing companies, just like we have done ourselves.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, France, Sweden
Investor stats
- Total investments: 94
- Round size: Seed $2.2M–$6M; Pre-Seed $1.3M–$2.3M; Series A $2.3M–$19M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Teemyco — Improve Engagement, Collaboration & Overall Happiness of Your Fully Online or Hybrid Team! Easy To Set Up & Integrates With Your Favorite Tools. 100% Free For Teams Up To 25 Users!
- Nostos Genomics — Our genetic variant interpretation platform enables genetic testing labs to give more people with genetic diseases a clear and fast diagnosis.
- Customs4trade (C4T) — Customs4trade simplifies Global Customs Management and Trade Compliance with a user-friendly software solution, CAS, which offers end-to-end automation.
GLS Ventures
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series B
- Geography: Austria
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Nabriva Therapeutics — MPOMM Adalah link resmi berlisensi agen mpo slot paling gacor hari ini dengan pilihan bermain di server slot anti rungkat terjamin kemenangan jackpot maxwin menang berapapun akan di bayar lunas
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Grant, Pre-Seed, Seed
- Geography: United Kingdom, Spain, Ireland
Investor stats
- Total investments: 95
- Round size: Seed $220k–$1.4M; Grant $22k–$1.6M; Pre-Seed $44k–$1.4M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- IDOVEN — IDoven develops products to detect heart problems at an early stage to prevent heart diseases.
- eBreathie — eBreathie is a pioneering digital health startup offering an integrated asthma management solution. Our system comprises a smart inhaler (a medical device) that not only tracks WHEN patients take their medication but also HOW they do it, creating a detailed inhalation profile for each use. Paired with a user-friendly mobile app for patients and acomprehensive patient management platform for doctors, we provide real-time feedback on inhalation efficacy, ensuring patients and healthcare professionals have the insights needed for optimal asthma management. Leveraging IoT and AI, our goal is to reduce emergency visits, asthma attacks, and hospitalizations while ensuring effective inhalation techniques and optimal patient care.
- Trak — Trak is a software tool for healthcare professional to provide AI-based tele-rehabilitation services like physiotherapy and others.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Join FoodTech focused investors looking to back impact-driven founders shaping our food system
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Food Processing
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 28
- Lead/follow: no public data
Portfolio highlights
- twig bio — twig bio operates as a bioengineering startup. twig bio using AI and robotics to find sustainable replacements for harmful ingredients.
- Cultivated Biosciences — Cultivated - Creamy, dairy-free indulgence
- UNCAGED Innovations — What if we could make leather without the animal? We are a biomaterials company combining the power of nature and technology to reimagine leather.
The Auxxo Female Catalyst Fund is a sector agnostic pre-seed and seed stage investors that backs female (co-)founded startups in Europe.
Show more...Investment focus
- Industry: Software, Health Care, FinTech
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, United Kingdom, France
Investor stats
- Total investments: 36
- Lead/follow: no public data
Portfolio highlights
- BIOVOX — Mit Biokunststoff aus nachwachsenden Rohstoffen bis zu 85% CO2 einsparen. Hergestellt unter ISO 13485, biokompatibel nach ISO 10993.
- Recyda GmbH — All-in-one Packaging Recyclability Management
- Exakt Health — Exakt Health is the physio app for sports injuries. The Exakt Health app guides users through self-diagnosis for frequent sports injuries and then creates an individualized rehabilitation plan.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 298
- Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $11M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Venture Partners AG is a leading European Venture firm with locations in Switzerland and Boston.
Show more...Investment focus
- Industry: Internet, Software, Biotechnology
- Stage:Seed, Series B
- Geography: Austria, United States
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Allcyte — At Exscientia, we combine the power of AI and human creativity to make safer and more sophisticated drugs available to all. Visit our website to find out more.
- apps4biz.com — At apps4biz.com™, ease-of-use and affordability are Their passion. They understand that a small business does not have the resources to learn, implement and fully utilize complex systems. apps4biz.com solutions enable you to quickly take advantage of your investment. And, you can easily tailor the apps4biz.com solution to accommodate your businessnow, and as your company grows.
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Norway, Sweden, Germany
Investor stats
- Total investments: 27
- Round size: Series A $4.3M–$79M; Series B $28M–$68M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $105M in 2021
Portfolio highlights
- Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
- Emergence Therapeutics — Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as anADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration. Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 94
- Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 41
- Round size: Seed $2.4M–$15M; Pre-Seed $125k–$7.8M; Series A $12M–$26M
- Lead/follow: 2% lead, 98% follow
Portfolio highlights
- Anima — Anima's online patient triage speeds up the clinical workflow 10x and allows providers to deliver the right care for patients within 24 hours.Millions of patients with serious problems are missed and die every year because there isn’t adequate information flow between medical appointments. Patients submit their problems and requests onAnimainstead of waiting for an appointment, and Anima sends an actionable report to their provider with trends, risks and recommendations.
- Aware — Aware is a mobile app for evaluating health data and for researching chronic diseases.
- Lindus — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Australia, United States
Investor stats
- Total investments: 162
- Round size: Seed $1.6M–$10M; Pre-Seed $549k–$3.8M; Series A $9.5M–$44M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- EntryLevel — Learn in an affordable, peer-driven environment over 6 weeks with mentors from top companies across the world such as Atlassian, Wise and more.
- VSPARTICLE — VSPARTICLE develops nanoparticle generators for various applications such as sensors, batteries, catalysis, solar cells, healthcare, additive manufacturing, nano safety, and more. It also enables research and industry to generate new materials at the push of a button.They specialize in nanoparticle production and integration. The technologyspeeds up the developments of customers by producing the desired nanoparticles on location and integrate them directly in the final product. VSPARTICLE was founded in 2014 and is headquartered in Delft, The Netherlands.
- Auriga Space — Next-generation space launch company providing frequent, sustainable and affordable transport to low Earth orbit
Crédit Agricole CIB specialises in the businesses of capital markets and investment and corporate banking.
Show more...Investment focus
- Industry: Energy, Solar, Renewable Energy
- Stage:Debt Financing, Series A, Post-IPO Debt
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 52
- Lead/follow: no public data
Portfolio highlights
- ARAUCO — ARAUCO is a diversified global company in the forestry industry. They use world-class technologies and processes throughout the value chain. They are present in the forestry, pulp, timber, panels and renewable energy businesses.
- Odata Brasil — Odata Brasil S.A. operates a network of data centers. The Company provides colocation services, as well as infrastructure solutions for electronic equipment.
- Terra-Gen — Terra-Gen was established in August 2007, led by an experienced executive management team averaging over 25 years of relevant industry experience. The team has contracted or re-contracted over 10,000 MW of power generation facilities and has developed or acquired over $25 billion in assets over their careers.
We are i&i Biotech Fund, partners of outstanding founders on their path to global success. We invest in innovative early stage Life Sciences startups.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Czech Republic, India, Spain
Investor stats
- Total investments: 10
- Lead/follow: no public data
Portfolio highlights
- Antiverse — Designing biologics for 100 challenging targets
- Captain T Cell — Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients. The company identifies novel high-efficiency TCRs for the development of T cell immunotherapies. It focuses on CMC- and preclinical development for their lead candidates.
- Casinvent Pharma — Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!INVEST AG is the investment arm of the Raiffeisen bank group of Upper Austria and is one of Austria’s leading private equity funds, managing a volume of 180 million euros. As an evergreen fund with an indefinite term, we are able to provide long-term stability and a solid foundation for future success, which is particularly relevant for anincreasing number of medium-sized companies facing a growing need for equity.The benefits of private equity:No personal liability of the partners No securities to weigh you down Greater risk capacity Since its founding in 1994, INVEST AG has already invested equity and mezzanine capital in more than 140 companies in a wide variety of sectors. Currently, 26 companies in Austria and the south of Germany trust in our expertise and benefit from our support in operational, commercial, and strategic matters.Whatever situation you find yourself in as a company and whatever problem you are seeking a custom-made solution to, be assured that you will always find us to be a highly experienced and reliable partner.
Show more...Investment focus
- Industry: Security, Hospitality, Food and Beverage
- Stage:Seed, Private Equity
- Geography: Austria, United States
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- NEOH USA — NEOH USA is a fast growing new food brand from Kirkland, WA and the leader in Crossbars. It satisfies your sweet tooth without the guilt. Crossbars taste as great as a candy bars but are protein bars.
- HeartBeat.bio — HeartBeat.bio is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies.
- RadarServices — RadarServices is the European market leader for proactive IT security monitoring and IT risk detection as managed services. The services uniquely combine automated detection of security relevant issues and risks with the analysis and assessment done by experts. Data never leaves the clients‘ premises.
We make early investments in global healthcare technology companies that address prevention, disease management and health system efficiency that are relevant to emerging AsiaWe believe that innovation can happen anywhere, from the streets of Dhaka to the labs of Oxford, however without the right support network, these solutions might notscale, or find the best world-changing application. This is where we can help.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Seed, Pre-Seed, Series A
- Geography: Estonia, Singapore, United Kingdom
Investor stats
- Total investments: 24
- Lead/follow: no public data
Portfolio highlights
- Prosoma — Prosoma was born out a need to provide more comprehensive care for cancer patients. We have found a fundamental lack of access to psychological care for patients who not only have to face a life-altering disease and treatment, but also crucially have a different set of needs than other psychological patients. Barriers to accessing psychologicalcare often include low numbers of therapists and clinicians in the area, financial or geographical limitations, and the general wellbeing of patients preventing them from attending meetings. All of these issues can be solved by modern technology.By using VR as part of, or when necessary, an alternative to traditional psychological treatment, we can reach patients that would otherwise be left without any support. They can use our tool at home or in the clinics whilst undergoing pharmacological treatment and chemotherapy.We hope to provide patients with a tool that will help them manage stress, cope with the burden of cancer, and eventually improve their quality of life.
- Lifeyear — Digital-first heart care. At scale.
- CareLoop Health — CareLoop, an innovation emerging from the University of Manchester, furnishes patients with digital support resources while simultaneously providing healthcare professionals with the means to monitor and track patient symptoms.
venture capital
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A, Series B
- Geography: Hungary, South Korea, United States
Investor stats
- Total investments: 26
- Round size: Seed $424k–$31M; Series A $1.3M–$2.3M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Iskra — Iskra offers web3 gaming opportunities using blockchain and rewards its stakeholders based on their participation.
- On Vacation — On Vacation is a chat-based concierge service where customers may get help making reservations and getting personalized and optimal tours from travel specialists.
- NextChapter — NextChapter is a digital commerce platform that acquires and operates Coupang and Naver-based online native brands in Korea. NextChapter is backed by BlueRun Ventures/BRV Capital Management, Goodwater Capital, Klim Ventures, Fast Ventures and Sandbox Network.NextChapter was founded in 2021 by Joshua Kwon and Jay Chung and is headquarteredin Seoul, Korea.
ICL Startup Accelerator focuses on foodtech and crop nutrition startups, innovative products, and accelerates their market penetration
Show more...Investment focus
- Industry: Biotechnology, Agriculture, Organic Food
- Stage:Seed
- Geography: Israel, Austria
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Lavie bio — LaVie Bio develops bacterial compositions that are sprayed on plants, used to coat seeds, or are integrated in the soil around the plant in order to improve the crop or the plant's features.
- Arkeon Biotechnologies — Arkeon converts CO2 into resources to power tomorrow's industries.
Simon Capital is an early-stage VC fund with €105M capital ready to invest in innovations that will improve our everyday lives, following the mission of investing “for the next generation”.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Seed, Series A, Series B
- Geography: Germany, Austria
Investor stats
- Total investments: 12
- Lead/follow: no public data
Portfolio highlights
- Infinite Roots — Mushlabs is a biotech company using fermentation to create the next generation of sustainable foods from the roots of mushrooms.
- Neople — Every employee deserves an assistant. Meet the Neople, and increase your productivity simply by starting a conversation with them. Trained on your documents, available in your pocket.
- Pacifico Biolabs — Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of sustainable and food alternatives.
EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Germany, Austria, Ireland
Investor stats
- Total investments: 11
- Round size: Series A $3.9M–$15M; Series B $20M–$70M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
- Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 99
- Lead/follow: no public data
Portfolio highlights
- Streaming21 — Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home.
- Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
- Precision Therapeutics — Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.
A genetic medicines company developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Corporate Round, Post-IPO Debt, Series A
- Geography: United States, Austria
Investor stats
- Total investments: 9
- Lead/follow: no public data
Portfolio highlights
- Agenus — Our mission is to the power of the immune system to bring affordable, curative therapies to cancer patients
- invIOs — invIOs is a private biotechnology company that specializes in the discovery and development of next-generation cancer therapies that empower and educate the immune system to fight cancer.
- Castle Creek Biosciences — Dedicated to making life better for people suffering from rare diseases with few or no treatment options
Wir wollen unser wichtigstes Erbe erhalten. Eine lebenswerte Erde.
Show more...Investment focus
- Industry: Farming, Renewable Energy, Solar
- Stage:Seed, Grant, Pre-Seed
- Geography: Switzerland, Germany, Austria
Investor stats
- Total investments: 8
- Lead/follow: no public data
Portfolio highlights
- Planeteers — We capture CO2 in water and unleash the potential of the oceans as the largest carbon sink on our planet.
- Infrascreen — The transparent aluminium screen for extra energy-savings in greenhouses. Thanks to it's low-e coating, it saves up to 20% more than a regular energy-saving screen
- Kynda — Keen 4 Greens offers a wide range of vegan products. Founded in 2019, Keen 4 Greens is based in Hamburg, Germany.
Led by Werner Lanthaler, Wlanholding invests in life sciences and sustainability, advancing innovation and growth in cutting-edge technologies.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed
- Geography: Austria
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- aTension.life — aTension.life is a company focused on advancing the diagnosis and treatment of hypertension through precision medicine. It employs cutting-edge mass spectrometry technology to identify the underlying causes of uncontrolled hypertension using a single blood sample. aTension.life aims to provide personalized diagnostic solutions that enhance patientcare and support laboratories with accurate and reliable tools. The company's mission is to improve the quality of life for hypertensive patients by making advanced diagnostics widely accessible and enabling more effective, individualized therapies.
Biotechnology VC funding in Austria at a glance
Stats across 105 deals from 138 investors.
Access all 138 VC funds in Austria Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology VC Funds in Austria investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 138 VC funds investing in Austria Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!